Clinicopathological Features and Oncological Outcomes of Early and Late Recurrence in Stage III Colorectal Cancer Patients after Adjuvant Oxaliplatin-Based Therapy

Table 2

Comparison between early recurrence and late recurrence of 128 stage III CRC patients after the adjuvant oxaliplatin-based regimen.

	Early recurrence (N = 47)		Late recurrence (N = 81)
	N	(%)	N	(%)
Gender					0.708
Female	17	(36.2)	32	(39.5)
Male	30	(63.8)	49	(60.5)
Age (years)					0.006
≤57	22	(46.8)	19	(23.5)
>57	25	(53.2)	62	(76.5)
Tumor size (cm)					0.922
≥5	17	(36.2)	30	(37.0)
<5	30	(63.8)	51	(63.0)
Location					0.869
Right-sided colon	15	(31.9)	27	(33.3)
Left-sided colon	32	(68.1)	54	(66.7)
Pathological staging
Depth of tumor invasion					0.803
T1 + T2 + T3	38	(80.9)	64	(79.0)
T4	9	(19.1)	17	(21.0)
Lymph node metastasis					0.722
N1	24	(51.1)	44	(54.3)
N2	23	(48.9)	37	(45.7)
Histopathology grade					0.463
Well differentiated	0	(0)	0	(0)
Moderately differentiated	39	(83.0)	71	(87.7)
Poorly differentiated	8	(17.0)	10	(12.3)
Lymph-vascular invasion					0.759
No	15	(31.9)	28	(34.6)
Yes	32	(68.1)	53	(65.4)
Perineural invasion					0.204
No	24	(51.1)	32	(39.5)
Yes	23	(48.9)	49	(60.5)
Preoperative serum CEA level (ng/ml)					0.076
<5	23	(48.9)	52	(63.0)
≥5	24	(51.1)	29	(35.8)
Postoperative serum CEA level (ng/ml)					0.059
<5	35	(74.5)	72	(88.9)
≥5	12	(25.5)	9	(11.1)
Cycles of oxaliplatin-based regimen (cycles)					<0.001
≤8	26	(55.3)	14	(17.3)
>8	21	(44.7)	67	(82.7)
Pattern of recurrence/distant metastasis					0.449
Local recurrence	20	(42.6)	29	(35.8)
Distal metastasis	27	(57.4)	52	(54.2)
Patient survival from first cycle of mFOLFOX					<0.001
Median (month)	23.3		39.7

CEA: carcinoembryonic antigen.